Evaluation of Antiproliferative Activity and Molecular Modeling Studies of Some Novel Benzimidazolone-Bridged Hybrid Compounds

Okan Güven, Emre Menteşe, Fatih Yılmaz, Adem Güner, Mustafa Emirik, Nedime Çalışkan, Dmytro Khylyuk · 2025

Read Evaluation of Antiproliferative Activity and Molecular Modeling Studies of Some Novel Benzimidazolone-Bridged Hybrid Compounds by Okan Güven, Emre Menteşe, Fatih Yılmaz, Adem Güner, Mustafa Emirik, Nedime Çalışkan, Dmytro Khylyuk (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12735921.txt.

Description

Okan Güven and co-authors design and test a new family of hybrid molecules against cancer cells. Their 2025 paper builds compounds on a benzimidazolone bridge, fused with parts drawn from thiophene, furan, and other drug-like fragments. Cancer's global toll frames the work: nearly ten million deaths in 2022, with more projected.

The team made the compounds, confirmed their structures, and dosed them against lung, breast, and cervical cancer cells plus a normal kidney line. Several killed cancer cells in a dose-dependent way, with cervical cells the most sensitive. Adding one ring type or a coumarin part sharply improved both strength and selectivity, giving low doses needed and sparing normal cells two to three times over. Computer docking against two cancer-relevant proteins supported the results. The authors name the best compounds as leads worth developing.

Catalog record

CREATOROkan Güven, Emre Menteşe, Fatih Yılmaz, Adem Güner, Mustafa Emirik, Nedime Çalışkan, Dmytro Khylyuk
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE84 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12735921

Browse the full library · About the Tower of Babel